BNGO Bionano Genomics: Price-to-Projected Revenue Ratio

Graphic logo of Bionano Genomics Inc. (BNGO)

Bionano Genomics, Inc. (BNGO) generates revenue through the long-term sale of chips for Saphyr systems, creating a high-margin payment stream. The forward P/S trend confirms this potential, while 0.40 captures the current value of the indicator. However, success depends on the pace of laboratory adoption and the volume of grants. Outsourcing hardware assembly while maintaining full control over proprietary software mitigates these risks.

BNGO Bionano Genomics Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Bionano Genomics, Inc.

- current price and projected stock value:
- company stock capitalization data:
Analysis of all company metrics:BNGO (Bionano Genomics Inc.)
Product sample of bionanogenomics.com

For Bionano Genomics, Inc. (BNGO), whose genome mapping systems are not yet generating stable profits, the estimated P/S ratio measures market capitalization against projected revenue, revealing the gap between investor expectations and actual business scaling. Analyzing the trend of the expected P/S allows for a determination of whether the share price is supported by confidence in sales growth or if the company is becoming vulnerable due to capital depletion and technological stagnation.

Analysis of competing companies

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Price-to-Projected Revenue Ratio|Codexis Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Sangamo BioSciences|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology)|Price-to-Projected Revenue Ratio metagenomi.co (MGX)|DTIL: Future Price to Revenue|Price-to-Projected Revenue Ratio Generation Bio Co. GBIO|BOLD: Market Cap to Projected Revenue|XCUR: Forward Price-to-Revenue Multiple|Imunon (IMNN) - Forward Price-to-Revenue Multiple|PHIO (RXi Pharmaceuticals) - Forward Price-to-Revenue Multiple|MBIO (Mustang Bio Inc) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio TransCode Therapeutics, Inc.|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.